Unable to display view head.php file not found.
 
 

James A. Reiffel, MD - Novel Oral Anticoagulants - Figure 27

Summary of Clinical Outcomes

This Figure summarizes the efficacy and safety outcomes of the higher, 150-mg dose of dabigatran versus warfarin in the RE-LY trial.[96] As seen in the in the Forrest plot, other than major GI bleeding everything favors dabigatran over warfarin and superiority in terms of stroke reduction of all types of stroke.

 Reiffel JA. Am J Med 2013; 126: 00-00.

Complete references for all slides

References

[96] Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.

Unable to display view foot.php file not found.